Navigation Links
Enrollment Complete in Pivotal Phase 3 Trial of Medidur(TM) FA for Diabetic Macular Edema
Date:10/8/2007

ATLANTA, Oct. 8 /PRNewswire/ -- Alimera Sciences Inc., a privately held ophthalmic pharmaceutical company, and pSivida Limited (Nasdaq: PSDV; ASX: PSD; Xetra: PSI), announced today that enrollment is complete for the FAME(TM) (Fluocinolone Acetonide in Diabetic Macular Edema) Study of Medidur(TM) FA for the treatment of Diabetic Macular Edema. FAME is a double masked, randomized, multi-center study that is following over 900 patients in the U.S., Canada, Europe and India for 36 months with safety and efficacy assessed at two years. Alimera Sciences and pSivida are jointly developing Medidur FA under a collaborative research and development agreement.

"Alimera Sciences is very excited to have completed enrollment in the FAME Study as this brings us closer to taking Medidur FA, the next generation of retinal drug delivery, to market and to our ultimate goal of delivering treatments that enrich patients' quality of life," said Alimera CEO Dan Myers.

Medidur, a tiny, injectable insert, is being studied as a way to deliver fluocinolone acetonide, a corticosteroid, to the retina for up to three years as a treatment for diabetic macular edema (DME). Using a proprietary 25 gauge injector system, an eye care professional injects the Medidur insert into the vitreous through a minimally invasive procedure in an outpatient setting.

"This marks an important milestone for the company in our profit sharing collaboration with Alimera. We are very pleased at the continued development of Medidur FA, based on our technologies that have already been approved for two back of the eye diseases. We are optimistic that Medidur FA will offer a solution to the large market we see for this product," said pSivida Limited Managing Director, Dr Paul Ashton.

Diabetic retinopathy (DR), a complication of diabetes mellitus, is the leading cause of blindness in the working-age population of developed countries. At any time during progression of diabetic retinopathy, pati
'/>"/>

SOURCE Alimera Sciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
2. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
3. Celsion Completes Enrollment in Phase I Liver Cancer Study
4. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
5. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
6. Valopicitabine Combined with Standard of Care Cleared Hepatitis C Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a Phase II Trial
7. Study Shows Advantages of Complete Phase Ib Trial Over Separate Phase I Trials
8. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
9. LANI completes Phase I in Japan and to commence Phase I in UK
10. GTx Announces Ostarine Improved Insulin Resistance among Elderly Patients in a Recently Completed Phase II Clinical Trial
11. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- Kindred Hospital Houston Northwest, with Wound Care Specialists, ... new outpatient wound healing center.  The wound healing ... hard to heal wounds. Chronic wounds include diabetic ... leg wounds related to blood flow issues, post-surgical ... wounds which are complex and demonstrate delayed healing. ...
(Date:7/11/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ... "Immunoprotein Diagnostic Testing Market - Forecasts to 2019: ... 6% and is expected to be valued at ... http://photos.prnewswire.com/prnh/20130307/600769 ... been segmented according to immunoprotein types which include ...
(Date:7/10/2014)... July 11, 2014  Major advances in radiation ... are being highlighted in a three-day Oncology Summit ... from 10-12 July, 2014.  Renowned national and international cancer experts ... practices and exchange knowledge on modern technologies making ... efficient. The Summit will address ...
Breaking Medicine Technology:Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... MOUNTAIN VIEW, Calif., Jan. 4, 2011 PneumRx, Inc. ... bringing innovation and improvements to the treatment of lung ... in working capital commitments.  The oversubscribed round was led ... both leading venture capital firms from Europe, and also ...
... CITY, Calif., Jan. 4, 2011 Arstasis is pleased ... to physicians, nurses, patients, and cath lab technicians across ... of physicians participating in Arstasis clinical trials and select ...  As of today, the company is making the simple-to-use, ...
Cached Medicine Technology:PneumRx, Inc. Raises $33 Million in Capital 2PneumRx, Inc. Raises $33 Million in Capital 3Nationwide Launch of Arstasis One Access Device Provides Cath Labs Across the U.S. an Alternative to Standard Arteriotomies and Vascular Closure Implants 2
(Date:7/11/2014)... 11, 2014 As part of ... Liebhard LLP has been closely monitoring the ongoing ... (FDA) Obstetrics and Gynecology Devices Panel, which ... the cancer risks associated with the use of ... to a report published by Dow Jones Business ...
(Date:7/11/2014)... July 11, 2014 Operators ... $50 billion in fuel costs now that ... current GHG standards are phasing ... it upon themselves to install new features ... 1.    Idle reduction technologies , 2.    Efficient driveline components ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 The ... Supplements, Specialty Nutrients, Animal Feed), Applications (Regular, Therapeutic, ... - Global Trends & Forecasts to 2019 ” ... an analysis and forecasting of the market value ... identifies the driving and restraining factors for the ...
(Date:7/11/2014)... disposable medical suppliers call for the biggest share of ... past two decades, the world market for disposable medical ... year), primarily owing to the importance of these products ... market for disposable medical supplies in the world, accounting ... held by Europe with a 29% market share. The ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 The ... five years to 2014 on the heels of fresh ... prompted farmers to dedicate a larger share of their ... More specifically, the regulations required the mixing of 5.0% ... biofuel production in the United States created a key ...
Breaking Medicine News(10 mins):Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 4Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 2Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 3Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 2Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 3
... draws attention to urgency in preventing stroke and supporting 6 million stroke ... ... This year nearly 795,000 people will have a stroke, leaving a path ... to National Stroke Association , which is observing National Stroke Awareness ...
... Everywhere, Inc. filed a federal complaint today seeking an injunction against the ... ... Everywhere, Inc . filed a federal complaint today seeking an injunction against ... import of Electronic Cigarettes. The company believes the use of inhaled nicotine ...
... provide telephone based triage and health advice to EosHealth service ... As EosHealth subscribers manage their health through interactive resources via ... health triggers and proactively reach out to perform triage and ... ...
... in Alzheimer,s disease, people become less efficient at separating ... found. , Knowing this, clinicians may be able ... to remember high-value information better, according to a report ... by the American Psychological Association. , Remembering what,s ...
... PARK, Calif., May 4 Acclarent, Inc., the pioneer ... the treatment of chronic sinusitis, announced today that the ... 7,500,971, entitled "Devices, Systems and Methods for Treating Disorders ... This patent and Acclarent,s earlier 7,462,175 patent are ...
... Steps to Prevent Spreading FluNORRISTOWN, Pa., May 3 ... first laboratory-confirmed case of 2009 A/H1N1 in a 31-year-old ... confirmed case, it is even more important for the ... can help prevent the spread of the flu," said ...
Cached Medicine News:Health News:Four of Five Families Will Be Touched by Stroke in 2009 2Health News:Press Release: Electronic Cigarette VS FDA 2Health News:SironaHealth to Provide 24 x 7 Nurse Line and Clinical Outreach to EosHealth as part of their Mobile Health & Wellness Programs 2Health News:SironaHealth to Provide 24 x 7 Nurse Line and Clinical Outreach to EosHealth as part of their Mobile Health & Wellness Programs 3Health News:Memory grows less efficient very early in Alzheimer's disease 2Health News:Acclarent, Inc. Granted Key Patent Covering Balloon Sinuplasty(TM) Technologies 2Health News:Governor Rendell Announces Pennsylvania's First Confirmed Case of 2009 A/H1N1 Flu 2Health News:Governor Rendell Announces Pennsylvania's First Confirmed Case of 2009 A/H1N1 Flu 3
For the qualitative detection of group A Streptococcal antigen from throat swabs...
For the qualitative detection of human Chorionic Gonadotrophin (hCG) in urine or serum specimens...
For the qualitative detection of human Chorionic Gonadotrophin (HCG) in urine or urine and serum specimens...
For the qualitative detection of human Chorionic Gonadotrophin (HCG) in urine or urine and serum specimens...
Medicine Products: